Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.

Authors
Raymond, E
Dahan, L
Raoul, J
Bang, Y
Borbath, I
Lombard-Bohas, C
Valle, Juan W
Metrakos, P
Smith, D
Vinik, A
Affiliation
Service Inter-Hospitalier de Cancérologie et Service de Gastroenteropancréatologie, Hôpital Beaujon, Clichy, France.
Issue Date
2011-02-10

Metadata
Show full item record
Abstract
The multitargeted tyrosine kinase inhibitor sunitinib has shown activity against pancreatic neuroendocrine tumors in preclinical models and phase 1 and 2 trials.
Citation
Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. 2011, 364 (6):501-13 N. Engl. J. Med.
Journal
New England Journal of Medicine
URI
http://hdl.handle.net/10541/201093
DOI
10.1056/NEJMoa1003825
PubMed ID
21306237
Type
Article
Language
en
ISSN
1533-4406
Collections